Skip to content
Cultural Foundation
Author:
Vaxcyte, Inc.
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
October 4, 2026
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
September 3, 2026
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026
Vaxcyte to Participate in Upcoming Investor Conferences
July 8, 2026
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
June 2, 2026
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
May 8, 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
March 23, 2026